Xencor Inc - XNCR
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 30, 2026 | SCHEDULE 13G | RA Capital Management, L.P. | 6.5% | 4,736,739 | View |
| Mar 30, 2026 | SCHEDULE 13G | Peter Kolchinsky | 6.5% | 4,736,739 | View |
| Mar 30, 2026 | SCHEDULE 13G | Rajeev Shah | 6.5% | 4,736,739 | View |
| Mar 30, 2026 | SCHEDULE 13G | RA Capital Healthcare Fund, L.P. | 6.5% | 4,736,739 | View |
| Mar 27, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 5.3% | 3,798,627 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF I GP LLC | 5.3% | 3,798,627 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 3.9% | 2,787,735 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF II GP LLC | 3.9% | 2,787,735 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.6% | 439,372 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.6% | 439,372 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 9.2% | 6,586,362 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 9.99% | 7,133,720 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF INC/IL | 9.99% | 7,133,720 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | LAMPERT MARK N | 9.99% | 7,133,720 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | EcoR1 Capital, LLC | 6.4% | 4,640,000 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Oleg Nodelman | 6.4% | 4,640,000 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | EcoR1 Capital Fund Qualified, L.P. | 6.0% | 4,354,981 | View |
| Dec 03, 2025 | SCHEDULE 13G/A | The Vanguard Group | 10.03% | 7,169,547 | View |
| Nov 14, 2025 | SCHEDULE 13G | RTW Investments, LP | 8.7% | 6,221,054 | View |
| Nov 14, 2025 | SCHEDULE 13G | Roderick Wong | 8.7% | 6,221,054 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | T. Rowe Price Associates, Inc. | 2.4% | 1,693,292 | View |
| Oct 31, 2025 | SCHEDULE 13G/A | The Vanguard Group | 9.95% | 7,103,758 | View |
| Oct 17, 2025 | SCHEDULE 13G | BIOTECHNOLOGY VALUE FUND L P | 3.5% | 2,467,127 | View |
| Oct 17, 2025 | SCHEDULE 13G | BVF I GP LLC | 3.5% | 2,467,127 | View |
| Oct 17, 2025 | SCHEDULE 13G | BIOTECHNOLOGY VALUE FUND II LP | 2.5% | 1,793,209 | View |
| Oct 17, 2025 | SCHEDULE 13G | BVF II GP LLC | 2.5% | 1,793,209 | View |
| Oct 17, 2025 | SCHEDULE 13G | Biotechnology Value Trading Fund OS LP | 0.4% | 286,542 | View |
| Oct 17, 2025 | SCHEDULE 13G | BVF Partners OS Ltd. | 0.4% | 286,542 | View |
| Oct 17, 2025 | SCHEDULE 13G | BVF GP HOLDINGS LLC | 6.0% | 4,260,336 | View |
| Oct 17, 2025 | SCHEDULE 13G | BVF PARTNERS L P/IL | 6.5% | 4,619,341 | View |
| Oct 17, 2025 | SCHEDULE 13G | BVF INC/IL | 6.5% | 4,619,341 | View |
| Oct 17, 2025 | SCHEDULE 13G | LAMPERT MARK N | 6.5% | 4,619,341 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.